Cargando…

Serum Levels of Il-12 and Il-23 in Breast Cancer Patients Infected with Toxoplasma gondii: A Case-Control Study

BACKGROUND: The possible risk factor of Toxoplasma infection and its possible correlation with Interleukin-12 (IL-12) and Interleukin-23 (IL-23) in breast cancer patients was investigated. METHODS: Overall, 190 female patients referred to the Oncology Teaching Hospital in the Medical City Hospital,...

Descripción completa

Detalles Bibliográficos
Autores principales: ASSIM, Maha Mustafa, SAHEB, Entsar Jabbar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039494/
https://www.ncbi.nlm.nih.gov/pubmed/33884003
http://dx.doi.org/10.18502/ijpa.v15i4.4850
Descripción
Sumario:BACKGROUND: The possible risk factor of Toxoplasma infection and its possible correlation with Interleukin-12 (IL-12) and Interleukin-23 (IL-23) in breast cancer patients was investigated. METHODS: Overall, 190 female patients referred to the Oncology Teaching Hospital in the Medical City Hospital, Baghdad, Iraq were enrolled from 2017–2018. All serum samples were tested for T. gondii immunoglobulins (IgG and IgM (antibodies and IL-12, IL-23 levels. RESULTS: In patients with breast cancer, the results revealed a high positivity percentage for anti-Toxoplasma IgG. In breast cancer patients infected with T. gondii, the IL-12 level was lower than the controls while the mean level of IL-23 was higher than the controls. According to the cancer grade in breast cancer patients infected with T. gondii, the higher mean titer of IgG and IL-23 was in grade 3 in contrast the highest mean titer of IL-12 was in grade 1. Concerning the tumor stages in breast cancer patients infected with T. gondii, the higher mean titer of IgG, IL-12 and IL-23 was in stage (III). According to the tumor size in breast cancer patients infected with T. gondii, the highest mean titer of IgG, IL-12 and IL-23 was in size >3cm. CONCLUSION: The levels of IL-23 could be a candidate as a non-invasive primitive marker for earlier prediction of breast cancer stage.